GHK-Cu already has strong name recognition in skin, hair, and cosmetic-aging conversations.
Popularity and non-injectable use do not answer the specific regulatory, formulation, or clinical questions FDA will review.
What a visitor should know.
Technical details: aliases, tracked claims, and data record
2 names in this peptide family.
Injectable GHK-Cu and non-injectable GHK-Cu have materially different FDA review contexts and are never collapsed into one legal-status claim.
4 evidence questions.
Human benefitLimited human evidenceDoes GHK-Cu have established human clinical benefit for uses to be specified in forthcoming meeting materials?
FDA approvalNo FDA approval identifiedIs GHK-Cu FDA approved?
503A statusRegulatory recordIs GHK-Cu on FDA's final 503A Bulks List or generally permitted because of committee activity?
Identity transferIdentity-sensitiveAre every product, alias, form, and related compound labeled GHK-Cu automatically interchangeable?
See every GHK-Cu evidence question →Open the machine-readable record ↗FDA placed the meeting before the end of February 2027
GHK-Cu remains one of five substances on the agenda. FDA has not yet posted the exact meeting date or compound-specific briefing materials.
The review has a public time window.
No committee recommendation or FDA decision has occurred.
How the FDA record developed.
This timeline separates early nominations and scientific reviews from committee votes and final FDA decisions.
FDA placed the meeting before the end of February 2027
GHK-Cu remains one of five substances on the agenda. FDA has not yet posted the exact meeting date or compound-specific briefing materials.
Read the source ↗FDA announced a future advisory review
GHK-Cu was named among five bulk drug substances scheduled for committee consideration.
Read the source ↗What has actually been studied?
Human studies appear on the left. Animal, cell, and laboratory studies appear on the right because they cannot establish that a treatment works in people.
FDA says the advisory review will happen before the end of February 2027, including the nominated non-injectable context.
Read the FDA review ↗Thirteen patients completed a study of topical GHK-Cu after laser resurfacing. Objective assessments found no significant advantage, although patient satisfaction was higher.
Read the study on PubMed ↗Preclinical evidence will be classified when FDA posts the meeting briefing materials.
Important unknowns.
- FDA has identified limited or absent human safety information for the nominated use context.
- Peptide impurities, aggregation, immunogenicity, or API characterization may be material concerns.
- Compound-specific FDA concerns are linked in the source record.
These are evidence and regulatory uncertainties, not an individualized assessment of whether a treatment is appropriate.
Read the original sources.
Technical change history and comparison data
2 dated changes. 1 comparison groups.
These records show what each source added and whether it changed Peplyst's public conclusion.